Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) shares shot up 2.9% during trading on Wednesday . The company traded as high as $10.39 and last traded at $10.33, with a volume of 132,457 shares changing hands. The stock had previously closed at $10.04.

A number of brokerages have recently commented on FOMX. TheStreet raised Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd. Zacks Investment Research raised Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a report on Tuesday, August 16th. Finally, Guggenheim reissued a “buy” rating and set a $20.00 price objective (up previously from $10.00) on shares of Foamix Pharmaceuticals in a report on Saturday, August 13th.

The stock’s 50 day moving average price is $8.82 and its 200-day moving average price is $7.18. The firm’s market cap is $314.58 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/foamix-pharmaceuticals-ltd-fomx-shares-up-2-9.html

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 21.87% and a negative net margin of 1,201.01%. On average, equities research analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.87) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Deerfield Management Co. raised its position in Foamix Pharmaceuticals by 35.1% in the second quarter. Deerfield Management Co. now owns 1,282,058 shares of the specialty pharmaceutical company’s stock valued at $8,141,000 after buying an additional 333,124 shares in the last quarter. BlackRock Fund Advisors raised its position in Foamix Pharmaceuticals by 1.4% in the first quarter. BlackRock Fund Advisors now owns 981,815 shares of the specialty pharmaceutical company’s stock valued at $6,401,000 after buying an additional 13,510 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Foamix Pharmaceuticals during the second quarter valued at $5,048,000. Opaleye Management Inc. raised its stake in shares of Foamix Pharmaceuticals by 17.8% in the second quarter. Opaleye Management Inc. now owns 695,000 shares of the specialty pharmaceutical company’s stock worth $4,413,000 after buying an additional 105,000 shares during the period. Finally, State Street Corp raised its stake in shares of Foamix Pharmaceuticals by 4.2% in the first quarter. State Street Corp now owns 293,003 shares of the specialty pharmaceutical company’s stock worth $1,908,000 after buying an additional 11,776 shares during the period. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

5 Day Chart for NASDAQ:FOMX

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.